A recent ⁢correction to published clinical trial data offers renewed ⁣optimism for children and young⁤ adults battling high-risk neuroblastoma,an aggressive cancer⁢ that develops ⁤from immature nerve cells. The findings, published online September 8, 2025, in Nature Medicine, detail the results of a phase 1/2 trial investigating GD2-targeting chimeric ⁢antigen receptor (CAR) T-cell therapy.

Neuroblastoma is most commonly diagnosed in young children, with high-risk cases - those that have spread to⁤ other parts of the body - carrying a particularly⁢ poor prognosis. Standard treatments ⁣include surgery, chemotherapy, radiation⁤ therapy, and stem cell transplant, but relapse rates remain high.